Table 1.
characteristics | Telomere length* (T/S ratio) | No. of cases | All-cause mortality
|
Breast cancer-specific mortality
|
||
---|---|---|---|---|---|---|
Death | HR (95%CI) | Death | HR (95%CI) | |||
All subjects | < 0.73 | 510 | 89 | 1.00 (Ref.) | 53 | 1.00 (Ref.) |
≥ 0.73 | 516 | 103 | 1.10 (0.83–1.46) | 54 | 1.01 (0.69–1.47) | |
Menopausal status | ||||||
Premenopausal | < 0.73 | 183 | 24 | 1.00 (Ref.) | 22 | 1.00 (Ref.) |
≥ 0.73 | 145 | 19 | 1.01 (0.55–1.84) | 13 | 0.75 (0.38–1.50) | |
Postmenopausal | < 0.73 | 315 | 62 | 1.00 (Ref.) | 28 | 1.00 (Ref.) |
≥ 0.73 | 359 | 82 | 1.16 (0.83–1.62) | 41 | 1.30 (0.81–2.11) | |
Cancer type** | ||||||
Invasive | < 0.73 | 418 | 83 | 1.00 (Ref.) | 50 | 1.00 (Ref.) |
≥ 0.73 | 430 | 96 | 1.07 (0.80–1.44) | 52 | 1.01 (0.69–1.50) | |
Tumor size** | ||||||
≥ 2cm | < 0.73 | 97 | 25 | 1.00 (Ref.) | 21 | 1.00 (Ref.) |
≥ 0.73 | 96 | 21 | 0.69 (0.38–1.25) | 13 | 0.53 (0.26–1.06) | |
ER status | ||||||
Positive | < 0.73 | 254 | 40 | 1.00 (Ref.) | 25 | 1.00 (Ref.) |
≥ 0.73 | 253 | 50 | 1.11 (0.73–1.69) | 26 | 1.05 (0.60–1.83) | |
Negative | < 0.73 | 72 | 23 | 1.00 (Ref.) | 16 | 1.00 (Ref.) |
≥ 0.73 | 86 | 26 | 0.87 (0.50–1.52) | 15 | 0.74 (0.37–1.50) | |
PR status | ||||||
Positive | < 0.73 | 254 | 40 | 1.00 (Ref.) | 25 | 1.00 (Ref.) |
≥ 0.73 | 253 | 50 | 1.11 (0.73–1.69) | 26 | 1.05 (0.60–1.83) | |
Negative | < 0.73 | 72 | 23 | 1.00 (Ref.) | 16 | 1.00 (Ref.) |
≥ 0.73 | 86 | 26 | 0.87 (0.50–1.52) | 15 | 0.74 (0.37–1.50) | |
HER-2/neu status | ||||||
Positive | < 0.73 | 325 | 67 | 1.00 (Ref.) | 41 | 1.00 (Ref.) |
≥ 0.73 | 344 | 65 | 0.85 (0.61–1.20) | 37 | 0.83 (0.53–1.29) | |
Negative | < 0.73 | 185 | 22 | 1.00 (Ref.) | 12 | 1.00 (Ref.) |
≥ 0.73 | 172 | 38 | 1.90 (1.12–3.22) | 17 | 1.62 (0.77–3.39) | |
Chemotherapy** | ||||||
Prior to | < 0.73 | 453 | 81 | 1.00 (Ref.) | 49 | 1.00 (Ref.) |
≥ 0.73 | 436 | 84 | 1.04 (0.77–1.41) | 43 | 0.91 (0.60–1.37) |
Median;
Sample sizes were less than 5 for select subgroups (breast cancer cases with in situ tumor stage, tumors <2 cm, and blood draw occurred after chemotherapy had been initiated) yielding unstable results, thus these data are not shown.